A phase II study of enzastaurin as second- or third-line treatment of non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Bepler, G.
Oh, Y.
Burris, H.
Cleverly, A.
Lahn, M.
Herbst, R. S.
机构：
[1] H Lee Moffitt Canc Ctr Res Inst, Tampa, FL USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Sarah Cannon Res Inst, Ashville, TN USA
[4] Eli Lilly & Co, Erlwood, England
[5] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7543
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Second- or third-line treatment with erlotinib in EGFR wild-type non-small cell lung cancer: Real-life data
    Debieuvre, D.
    Moreau, L.
    Coudert, M.
    Locher, C.
    Asselaine, B.
    Coetmeur, D.
    Dayen, C.
    Goupil, F.
    Martin, F.
    Brun, P.
    De Faverges, G.
    Hauss, P-A
    Gally, S.
    Yahia, B. Ben Hadj
    Grivauxd, M.
    REVUE DES MALADIES RESPIRATOIRES, 2019, 36 (06) : 649 - 663
  • [22] Treatment paradigms for patients with metastatic non-small cell lung cancer, squamous lung cancer: first second, and third-line
    Al-Farsi, Abdulaziz
    Ellis, Peter Michael
    FRONTIERS IN ONCOLOGY, 2014, 4
  • [23] COST-EFFECTIVENESS OF CRIZOTINIB FOR SECOND AND THIRD-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN ECUADOR
    Freire, V
    Cabezas, M.
    Salcedo, E.
    Albert, A.
    VALUE IN HEALTH, 2018, 21 : S30 - S31
  • [24] Efficacy and Toxicity of Pemetrexed as a Third-line Treatment for Non-small Cell Lung Cancer
    Sun, Jong-Mu
    Lee, Keun-Wook
    Kim, Jee Hyun
    Kim, Yu Jung
    Yoon, Ho Il
    Lee, Jae-Ho
    Lee, Choon-Taek
    Lee, Jong Seok
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2009, 39 (01) : 27 - 32
  • [25] Third-line therapy in advanced non-small cell lung cancer
    Geng, Zhen Ying
    Jiao, Shun Chang
    Liu, Shi Cui
    Li, Ying
    Liu, Zhe Feng
    Zhang, Guo Qing
    Wang, Li Jie
    Qu, Feng
    JOURNAL OF BUON, 2013, 18 (04): : 899 - 907
  • [26] Third-line therapy and beyond for patients with advanced/metastatic non-small cell lung cancer (NSCLC).
    Corral Jaime, Jesus
    Gonzalez de la Pena, Miriam
    Alonso, Miriam
    Sanchez Gastaldo, Amparo
    Dolores Mediano, Maria
    Amerigo, Marta
    Enrique Robles, Carlos
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [27] Everolimus and Erlotinib as Second- or Third-Line Therapy in Patients with Advanced Non-Small-Cell Lung Cancer
    Papadimitrakopoulou, Vassiliki A.
    Soria, Jean-Charles
    Jappe, Annette
    Jehl, Valentine
    Klimovsky, Judith
    Johnson, Bruce E.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (10) : 1594 - 1601
  • [28] Prevalence and effectiveness of third-line therapy for advanced non-small cell lung cancer (A-NSCLC)
    Ferreira, Catarina
    Fernandes, Ligia
    Figueiredo, Ana
    Barata, Fernando
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40
  • [29] Third-line chemotherapy with gemcitabine or docetaxel in patients with advanced non-small cell lung cancer (NSCLC).
    Morgensztern, D
    Lim, WT
    Subramanian, J
    Viswanathan, A
    Govindan, R
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 694S - 694S
  • [30] Vorinostat (V) and bortezomib (B) as third-line treatment in patients with advanced non-small cell lung cancer (NSCLC): A Wisconsin Oncology Network Phase II Study.
    Jones, M. W.
    Zhang, C.
    Oettel, K. R.
    Blank, J. H.
    Robinson, E. G.
    Ahuja, H. G.
    Kirschling, R. J.
    Johnson, P. H.
    Huie, M. S.
    Kolesar, J.
    Wims, M. B.
    Hernan, H.
    Campbell, T. C.
    Traynor, A. M.
    Hoang, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345